Tϸ°ûÏÎ½ÓÆ÷£¨TCE£©×÷ÓûúÖÆÓë¼¼Êõƽ̨

    ϸ°û¶¾ÐÔTϸ°ûÊǰ©Ö¢»¼ÕßÖÎÁƹý³ÌÖÐЧÁ¦×î¸ßµÄÃâÒßϸ°ûȺ¡£1992Äê£¬ÖØ×éIL-2£¨Ò»ÖÖTϸ°û»î»¯Ï¸°ûÒò×Ó£©»ñµÃÅú×¼£¬ÒÔ¼°Tϸ°û¼ì²éµãÒÖÖÆ¼Á£¨ÈçPD-1Þ׿¹¿¹ÌåÅÁ²©ÀûÖéµ¥¿¹ºÍÄÉÎäÀûÓȵ¥¿¹£©µÄÁÙ´²Ó°Ï죬»ñµÃÁËTϸ°ûÔÚ°©Ö¢ÖÎÁÆÖÐÖØÒªÐÔµÄÔçÆÚÁÙ´²Ö¤¾Ý¡£¸üÖ±½ÓµÄÖ¤¾ÝÀ´×Ô×ÔÌåÖ×Áö½þÈóTϸ°û£¨TILs£©µÄÖÎÁÆ·½·¨£¬¸ÃÁÆ·¨ÓëÇåÁÜÖÎÁƺÍIL-2Ïà½áºÏ£¬ÔÚºÚÉ«ËØÁöºÍÂѳ²°©»¼ÕßÖвúÉúÁËÇ¿Áҵķ´Ó¦¡£µ±×ÔÌåTϸ°û±»¸ÄÔìΪ±í´ïÖØ×éǶºÏ¿¹Ô­ÊÜÌ壨CAR£©Ê±£¬Ö»ÒªËüÃÇÄܹ»¶Ôϸ°û±íÃæ¿¹Ô­½øÐÐÖ÷Òª×éÖ¯ÏàÈÝÐÔ¸´ºÏÌ壨MHC£©·ÇÒÀÀµÐÔʶ±ð£¬¾Í¿ÉÒÔÔÚÒºÌåÖ×ÁöÖй۲쵽¸ßÍêÈ«»º½âÂʺͳ־÷´Ó¦£¬ÒÑÓм¸ÖÖ°ÐÏòCD3»òBCMAµÄCAR-TÁÆ·¨»ñµÃÅú×¼¡£¾¡¹Üϸ°ûÁÆ·¨ÔÚ·ÇʵÌåÁöÖлñµÃÁÙ´²³É¹¦£¬µ«¸ÃÖÎÁÆ¿ÉÄܾßÓÐÏÔÖø¶¾ÐÔ£¬ÇÒÔÚʵÌåÁöÖеĻîÐÔÓÐÏÞ¡£

    Tϸ°ûÏÎ½ÓÆ÷£¨TCE£©Óë×÷ÓûúÖÆ

    Tϸ°ûÏÎ½ÓÆ÷£¨T cell engager, TCE£©ÊÇϸ°ûÒò×Ó¡¢¼ì²éµãÒÖÖÆ¼ÁºÍTϸ°ûÁÆ·¨µÄÌæ´úÁÆ·¨£¬ËüÃÇͨ³£»ùÓÚ¿¹Ìå»ò¿¹Ì寬¶Î£¬Äܹ»½«ÌåÄÚÈκÎTϸ°ûÓë±í´ïÑ¡¶¨±íÃæ±êÖ¾ÎïµÄϸ°ûÁ¬½ÓÆðÀ´¡£TCE¿ÉÒÔ¾«È·¿ØÖƼÁÁ¿ºÍÉãÈëʱ¼ä£¬ÓÐÖúÓÚ×î´óÏ޶ȵؼõÉÙ¸±×÷Ó㬲¢ÇÒÉú²ú¹ý³Ì±Èϸ°ûÁÆ·¨Òª¼òµ¥µÃ¶à¡£°ÐÏòCD19¡¢CD20¡¢BCMAµÄTCEÔÚ¸´·¢/ÄÑÖÎÐÔ£¨r/r£©¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¨ALL£©¡¢·Ç»ôÆæ½ðÁܰÍÁö£¨NHL£©¡¢¶à·¢ÐÔ¹ÇËèÁö£¨MM£©ÒѾ­¹Û²ìµ½ÁîÈËÐÅ·þµÄÍêÈ«»º½âÂÊ¡£

    TCEÒ»¸ö±Û°ÐÏòÖ×ÁöÏà¹ØÏ¸°û±íÃæ¿¹Ô­£¨TAA£©£¬ÁíÒ»¸ö±Û°ÐÏòTCR-CD3¸´ºÏÎïÖÐCD3¦ÅÑÇ»ù£¬½áºÏ°©Ö¢Ï¸°ûºÍTϸ°û¡£ÕâÖÖ½áºÏ´Ù½øTϸ°ûºÍ°©Ï¸°ûÖ®¼äÃâÒßÍ»´¥µÄÐγɣ¬Tϸ°û¿ÉÒÔͨ¹ýÍ»´¥½«´©¿×ËØºÍ¿ÅÁ£Ã¸×¢Èëµ½¸½×ŵݩϸ°ûÖС£Í»´¥µÄÐγÉÒýÆðTCR½»ÁªºÍTϸ°û»î»¯£¬Òý·¢´ÙÑ×ϸ°ûÒò×ÓµÄÊÍ·Å£¬ÓÕµ¼Tϸ°ûÔöÖ³¡£´ÓÀíÂÛÉϽ²£¬Ã¿ÖÖϸ°û¶¾ÐÔTϸ°û±íÐͶ¼¿ÉÒÔͨ¹ýÕâÖÖ·½Ê½½áºÏ²¢²ÎÓëÁ¬Ðø°©Ï¸°ûÁѽ⣬°üÀ¨CD8+Tϸ°û£¬CD4+Tϸ°û£¬¦Ã/¦ÄTϸ°ûºÍNKTϸ°û¡£Í¨¹ýʶ±ðϸ°û±íÃæ¿¹Ô­£¬TCEʹµÃTϸ°ûµÄ»î»¯°ÚÍÑÁËMHC·Ö×Ó¡¢¿¹Ô­ëļӹ¤ºÍ³ÊµÝÒÔ¼°TCRÌØÒìÐÔµÄÏÞÖÆ¡£

    TCE-mechanism

    TCE¼¼Êõƽ̨

    IgG-like TCE

    • Mosunetuzumab£¨Genentech, Inc.£©

      Mosunetuzumab²ÉÓÃknobs-into-holes¼¼Êõ½øÐÐÖØÁ´Åä¶Ô£¬²ÉÓÃÌåÍâÍË»ð¼¼Êõ½øÐÐÖØÇáÁ´Åä¶Ô£¬Òѱ»Åú×¼ÓÃÓÚÖÎÁÆR/RÂËÅÝÐÔÁܰÍÁö£¨FL£©¡£

      Mosunetuzumab

    • Teclistamab£¨JNJ£©

      TeclistamabÊÇÒ»ÖÖ»ùÓÚGenmab¹«Ë¾¿ª·¢DuoBody?ƽ̨µÄTCE£¬°ÐÏòBCMA/CD3£¬ÒÑÉÏÊÐÓÃÓÚÖÎÁÆr/r¶à·¢ÐÔ¹ÇËèÁö£¨MM£©¡£

      DuoBody?ƽ̨ÀûÓÃÏÞÖÆÐÔFab±Û½»»»¼¼Êõ£¨controlled Fab-arm exchange, cFAE£©£¬ÔÚÁ½¸öIgG¿¹ÌåµÄCH3ÇøÓò·Ö±ðÒýÈëK409RºÍF405LÍ»±ä£¬ÀûÓò¸È鶯Îïϸ°û±í´ïϵͳ½øÐе¥¶ÀµÄÖØ×é±í´ïÓë´¿»¯£¬Ëæºó½«Á½ÖÖ¿¹ÌåÔÚ¶¨ÖÆÌõ¼þÏÂÀûÓÃcFAEÖØÐÂ×éºÏ£¬¼´¿É¸ßЧ×é×°»ñµÃ¾ßÓÐÕý³£IgG½á¹¹µÄË«ÌØÒìÐÔ¿¹Ìå¡£Teclistamab¿¹Ìå¹Ç¼ÜΪIgG4ÑÇÐÍ£¬ÐèÒª¶ÔÆä½øÐÐPAAÍ»±ä£¨S228P L234A/L235A£©³ýÈ¥IgG4µÄÌìÈ»FAE¹ý³ÌºÍFcµÄÏà¹ØÏìÓ¦¹¦ÄÜ£¨ADCC£¬CDC£©¡£

      Teclistamab

    • Epcoritamab£¨AbbVie & Genmab£©

      EpcoritamabÒ²»ùÓÚDuoBody?ƽ̨£¬×î½ü±»Åú×¼ÓÃÓÚÖÎÁÆR/RÃÖÂþÐÔ´óBϸ°ûÁܰÍÁö£¨DLBCL£©¡£

    • ERY974£¨Chugai£©

      ERY974ÊÇÒ»ÖÖ°ÐÏòGlypican-3£¨GPC3£©µÄTCE£¬ÓÃÓÚÖÎÁÆÊµÌåÁö£¬Ä¿Ç°´¦ÓÚÁÙ´²Ç°¿ª·¢½×¶Î¡£ËüµÄ¹¹½¨ÊÇͨ¹ýÔÚCH3½á¹¹ÓòÒýÈë¾²µçתÏòÍ»±äÀ´Çý¶¯ÖØÁ´µÄÒìÔ´¶þ¾Û»¯£¬Í¬Ê±ÀûÓù²Í¬ÇáÁ´À´±ÜÃâÇáÁ´µÄ´íÅ䣨ART-Ig£©¡£

    • REGN1979£¨Regeneron£©

      REGN1979Ϊ°ÐÏòCD20/CD3µÄTCE£¬¸ÃTCEʹÓù²Í¬ÇáÁ´£¬²¢ÔÚÖØÁ´CH3ÇøÓòÖÐÒýÈëÍ»±ä£¬ÐγÉIgG1/IgG2/IgG4ÓëIgG3µÄ¾Ö²¿Í¬ÐÍǶºÏÌ壬ÀûÓõ°°×ÖÊAµÄÑ¡ÔñÐÔ´¿»¯»ñµÃË«ÌØÒìÐÔ¿¹Ìå¡£REGN1979ÏÖÕýÔÚÊÊÓ¦Ö¢¶ñÐÔÁܰÍÁö£¨B-NHL£©µÄÁÙ´²ÊÔÑéÖС£

      REGN1979

    ÕâÖÖTCE½á¹¹ÓÐÍû³ÉΪһÖÖÐÂÆ½Ì¨¡£»ùÓÚ¸ÃÆ½Ì¨£¬»¹ÓÐһЩÓÃÓÚÖÎÁÆÊµÌåÁöµÄTCE£¬°üÀ¨REGN4018¡ª¡ª°ÐÏòMUC16/CD3£¬ÓÃÓÚÖÎÁÆÂѳ²°©£¨OC£©ºÍREGN4336¡ª¡ª°ÐÏòPSMA/CD3£¬ÓÃÓÚÖÎÁÆ×ªÒÆÐÔÈ¥ÊÆµÖ¿¹ÐÔǰÁÐÏÙ°©£¨mCRPC)£¬ÕýÔÚÁÙ´²ÊÔÑéÖС£

    »ùÓÚ¿¹Ì寬¶ÎµÄTCE

    ËäÈ»Fc-like TCE¾ßÓÐÌìÈ»IgGµÄÌØÐÔ£¬ÓÐÀûÓÚ¿¹ÌåÒ©ÎïµÄÖÆ±¸ºÍPK/ADAÌØÐÔ£¬µ«»ò³öÓÚ¶ÀÌØµÄÒ½ÁÆÄ¿µÄ£¬»òÓÉÓÚÉú²ú¹¤ÒÕ¼¼Êõ»òÉÌÒµÏÞÖÆ£¬»ùÓÚ¿¹Ì寬¶ÎµÄTCEÒ²Öð½¥×ßÈëÊÓÏß¡£

    »ùÓÚ¿¹Ì寬¶ÎµÄTCEͨ³£ÊÇ¡ª¡ª

    • ÓÉÁ´½ÓµÄscFvs, scFabs»òsVDsµÈ×é³ÉµÄ¼òµ¥½á¹¹
    • ȱÉÙ°ëË¥ÆÚÑÓ³¤£¨HLE£©²¿·Ö
    • ÄÑÒÔÉú²ú£¬ÈÝÒ×¾ÛºÏ/Ë鯬
    • Ìå»ýС£¬°ëË¥ÆÚ¶Ì

    ÕâÀàTCEµÄ´ú±íÊÇAmgen¹«Ë¾»ùÓÚBiTE?ƽ̨£¬°ÐÏòCD19/CD3µÄBlinatumomab£¬Òѱ»Åú×¼ÓÃÓÚÖÎÁƳÉÈ˼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¨BCP-ALL£©¼°ºóÐø¸ü¶àµÄÊÊÓ¦Ö¢¡£

    ΪÁËÑÓ³¤°ëË¥ÆÚ£¬¼õÉÙ¸øÒ©ÆµÂÊ£¬AmgenÔÚBiTE?ÉÏÈÚºÏFc½á¹¹Óò£¬²úÉúÁËһϵÁÐHLE BiTE·Ö×Ó£¨·Ö×ÓÁ¿Ô¼Îª106 kD£©¡£AMG757ÊÇÒ»ÖÖ°ÐÏòDLL3µÄHLE BiTEs£¬Ä¿Ç°ÕýÔÚÑо¿ÓÃÓÚ¸´·¢ÐÔСϸ°û·Î°©£¨SCLC£©ÖÎÁÆ¡£

    ÒÔÀàËÆµÄ·½Ê½£¬MacroGenics¿ª´´ÁËDARTƽ̨²¢ÒÔ´ËÆ½Ì¨Éè¼ÆÁËÖÎÁÆÐÔ·Ö×Ó£¬ÕâЩ·Ö×Ó½«Á½¸ö¶ÀÁ¢µÄfabÒÔÒìÔ´¶þ¾ÛÌå½á¹¹½áºÏÔÚÒ»Æð£¬¿É¸ù¾Ý°ëË¥ÆÚ³¤¶Ì½øÐе÷Õû£¬¾ßÓлò²»¾ßÓÐFc½á¹¹Óò¡£MGD024ÊÇÒ»ÖÖÓÃÓÚÖÎÁÆr/r CD123(+)ѪҺϵͳ¶ñÐÔÖ×Áö»¼ÕߵİÐÏòCD123/CD3µÄDart TCE£¬Ä¿Ç°ÒѽøÈëÁÙ´²Ñо¿¡£

    Fragment-based-TCE1

    Harpoon¹«Ë¾¿ª·¢ÁËÕë¶ÔʵÌåÁöºÍѪҺϵͳ¶ñÐÔÖ×ÁöTϸ°û¼¤»îÐԶ๦ÄÜ¿¹Ì壬¿¹Ìå»ùÓÚÆä´´½¨µÄTriTAC¡¢ProTriTAC£¨Ç°Ò©£©ºÍTriTAC-XRÈý¸öÈýÌØÒ쿹ÌåÆ½Ì¨£¬ÕâЩTCEƽ̨ÒýÈëÁ˵¥Óò¿¹Ì壬²¢Í¨¹ý½áºÏ°×µ°°×À´ÑÓ³¤°ëË¥ÆÚ¡£

    TriTAC½öº¬ÓÐÒ»ÌõëÄÁ´£¬°üº¬Èý¸ö½á¹¹Óò£¬·Ö±ð½áºÏCD3£¬ÈËѪÇå°×µ°°×ºÍTAA¡£ÆäÖнáºÏCD3±íλµÄ¿¹ÌåΪµ¥Á´¿¹Ì壨scFv£©£¬½áºÏÈËѪÇå°×µ°°×ºÍTAAµÄ¿¹ÌåΪÄÉÃ׿¹Ìå¡£
    ´ËÍ⣬Immunocore¹«Ë¾¿ª·¢µÄµÚÒ»ÖÖÒ²ÊÇΨһһÖÖ±»Åú×¼ÓÃÓÚʵÌåÁö£¨ð¤Ä¤ºÚÉ«ËØÁö£¬mUM£©ÖÎÁƵÄTCE¡ª¡ªTebentafusp-tebn£¨KIMMTRAK£©£¬ÓÉTCRmºÍ°ÐÏòCD3µÄscFv×é³É¡£

    Fragment-based-TCE2

    ÆäËûÀàÐ͵ÄTCE

    • EMB-07/EMB-06

      EMB-07ÊÇÀûÓÃEpimAbµÄFIT-Igƽ̨Éè¼ÆµÄ£¬°ÐÏòROR1/CD3µÄTCE£¬ÓÃÓÚʵÌåÁöµÄÖÎÁÆ£¬Ä¿Ç°ÕýÔÚ½øÐÐÁÙ´²ÆÀ¹À¡£

      Appended-IgGÔÚ³£¹æIgGÉϸ½¼ÓscFv¡¢Fab»òÄÉÃ׿¹Ìå¡£ËüÃǵİëË¥ÆÚÓëÇ×´úIgGÏ൱¡£È»¶ø£¬·Ç×ÔÈ»½á¹¹¿ÉÄÜ»áÔö¼Ó¾Û¼¯ÐÔ¡¢²»Îȶ¨ÐÔºÍADA·çÏÕ¡£FIT-Igƽ̨ÔÚ²»ÒýÈëÍ»±ä»òÁ¬½Ó×Ó£¨linker£©µÄÇé¿öϲúÉúË«ÌØÒìÐÔ¿¹Ì壬ÓÐÀûÓÚÆäÖÆ±¸ºÍÎȶ¨ÐÔ¡£

      EMB-06ÊÇÁíÒ»ÖÖ»ùÓÚFIT-Igƽ̨µÄ°ÐÏòBCMAµÄTCE£¬Ä¿Ç°Ò²ÔÚÁÙ´²ÆÀ¹ÀÖС£

    • BA1202

      BA1202ΪBoan Biotech°ÐÏòCEA/CD3µÄ¶Ô³ÆÈý¼Ûµ¥Á´¿¹Ì壬Æä¾ßÓÐÀàËÆºûµûÐεĿ¹Ìå½á¹¹£ºFab¶ËÓëCEAË«¼Û½áºÏ£¬¶øÇáÁ´C¶ËÁ¬½ÓµÄ¶þ¼Ûµ¥Á´¿¹ÌåÓëCD3µ¥¼Û½áºÏ£¨¿ÉÄÜÊÇÓÉÓڿռ乹ÏóµÄ¸Ä±ä»òÇ׺ÍÁ¦½µµÍ£©£¬Ä¿Ç°ÒѽøÈëÁÙ´²ÊÔÑé½×¶Î¡£

    • Cibisatamab (RG7802)

      CibisatamabÊÇÒ»ÖÖ°ÐÏòCEA/CD3µÄTCE£¬Í¨¹ý½«µÚ¶þ¸öÓëCEA½áºÏµÄFabÇøÌí¼Óµ½¶Ô³ÆKIH½á¹¹À´ÊµÏÖÓë¼²²¡°ÐµãµÄ¡°µÍÇ׺ÍÁ¦£¨affinity£©¸ßÇ׺ÏÁ¦£¨avidity£©¡±½áºÏ£¬ÊÔͼͨ¹ý¼õÉÙÍѰж¾ÐÔÀ´ÊµÏÖÁÆÐ§ºÍ°²È«ÐÔµÄÆ½ºâ¡£Ä¿Ç°¸ÃTCEÕýÔÚÁÙ´²ÊÔÑéÖС£

      TCE-Other-Than-Discussed1

    • CX-904

      CX-904ÊÇÓÉCytomx¹«Ë¾Îª¾«×¼°ÐÏòÉè¼ÆµÄǰÌåÒ©ÎÔÚÖ×Áö΢»·¾³ÖÐͨ¹ýÌØÒìÐÔµ°°×Ë®½âÌõ¼þ±»¼¤»î£¬°ÐÏòEGFR/CD3£¬Ä¿Ç°ÕýÔÚÁÙ´²ÊÔÑéÖС£

    • Imvotamab (IGM-2323)

      ImvotamabÊǰÐÏòCD20ºÍCD3µÄIgMͬÖÖÐÍTCE¡£ImvotamabÓµÓÐ10¸öCD20½áºÏÓò£¬±ÈIgGͬÖÖÐ͵Ŀ¹ÌåÓиü¸ßµÄÇ׺ÏÁ¦£¬´Ó¶øÄܹ»¿Ë·þ°Ðµã¼õÉÙÒýÆðµÄÄÍÒ©£¬²¢ÊµÏÖ±ÈĿǰÒÑÅú×¼µÄ¿¹ÌåÁÆ·¨¸üºÃµÄÁÆÐ§¡£¸Ã¹«Ë¾¸ü¶àµÄIgM TCEÒ©Îï°üÀ¨IgM-2644(CD38/CD3)ºÍIgM-2537(CD123/CD3)¡£

    • TNB-486

      TNB-486ÊÇÒ»ÖÖÓÉTenobio¹«Ë¾¿ª·¢°ÐÏòCD19µÄ²»¶Ô³ÆTCE¡£ËüµÄÐÎʽ½éÓÚIgG-like TCEºÍ»ùÓÚ¿¹Ì寬¶ÎTCEÖ®¼ä¡£ËüÓÉÒ»°ë½áºÏCD3µÄIgGºÍÒ»°ë½áºÏCD19µÄÖØÁ´¿¹Ì壨HcAb£©×é³É£¬Ä¿Ç°ÕýÕë¶Ôr/r BÁܰÍÁö½øÐÐÁÙ´²ÆÀ¹À¡£

    • YBODY

      ÓëTNB-486¸ñʽÏàËÆ£¬YZYBio¹«Ë¾µÄYBODYƽ̨ÓÉÒ»°ëÓë¼²²¡°Ðµã½áºÏµÄIgGºÍÒ»°ëÓëCD3½áºÏµÄscFv×é³É¡£Ò»Ð©»ùÓÚYBODYƽ̨µÄTCEĿǰÕýÔÚÁÙ´²ÊÔÑéÖУ¬ÈçM802£¨HER2/CD3£©¡£

      TCE-Other-Than-Discussed2

    ²Î¿¼ÎÄÏ×
    [1]Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol. 2022 Sep 1;34(5):552-558. doi: 10.1097/CCO.0000000000000869.
    [2]Pillarisetti K, Powers G, Luistro L, et al.Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393.
    [3]Smith, E., Olson, K., Haber, L. et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 5, 17943 (2016). https://doi.org/10.1038/srep17943.

    Ïà¹Ø·þÎñ

    Ïà¹ØÔĶÁ

    Á¢¼´Ñ¯¼Û
    • ÐÕÃû

    • µ¥Î»

    • µç»°

    • ×ÉѯÏîÄ¿

    • ÑéÖ¤Âë

    • ÁôÑÔ:

    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿